CLINICAL TRIALS PROFILE FOR DROSPIRENONE; ESTRADIOL

All Clinical Trials for DROSPIRENONE; ESTRADIOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00102141 ↗	Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women	Completed	Bayer	Phase 3	2004-04-01	The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.
NCT00356447 ↗	Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.	Completed	Bayer	Phase 3	2006-05-01	The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.
NCT00413062 ↗	Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-06-01	The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.
NCT00420342 ↗	Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension	Completed	Bayer	Phase 2	2007-01-01	The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
NCT00446199 ↗	Low-dose Hormone Therapy for Relief of Vasomotor Symptoms	Completed	Bayer	Phase 3	2007-03-01	The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
NCT00511199 ↗	Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-05-01	The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.
NCT00511433 ↗	Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-10-01	The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function.

Clinical Trial Conditions for DROSPIRENONE; ESTRADIOL

Condition Name

Condition Name for DROSPIRENONE; ESTRADIOL
Intervention	Trials
Contraception	11
Polycystic Ovary Syndrome	6
Premenstrual Syndrome	4
Healthy	4

Condition MeSH

Condition MeSH for DROSPIRENONE; ESTRADIOL
Intervention	Trials
Polycystic Ovary Syndrome	7
Syndrome	6
Premenstrual Syndrome	4
Endometriosis	4

Clinical Trial Locations for DROSPIRENONE; ESTRADIOL

Trials by Country

Trials by Country for DROSPIRENONE; ESTRADIOL
Location	Trials
United States	140
China	26
Germany	23
Austria	9
United Kingdom	7

Trials by US State

Trials by US State for DROSPIRENONE; ESTRADIOL
Location	Trials
Pennsylvania	8
Florida	8
California	8
Texas	7
Arizona	6

Clinical Trial Progress for DROSPIRENONE; ESTRADIOL

Clinical Trial Phase

Clinical Trial Phase for DROSPIRENONE; ESTRADIOL
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	7

Clinical Trial Status

Clinical Trial Status for DROSPIRENONE; ESTRADIOL
Clinical Trial Phase	Trials
Completed	40
Unknown status	7
Recruiting	6

Clinical Trial Sponsors for DROSPIRENONE; ESTRADIOL

Sponsor Name

Sponsor Name for DROSPIRENONE; ESTRADIOL
Sponsor	Trials
Bayer	22
Chulalongkorn University	3
Cairo University	3

Sponsor Type

Sponsor Type for DROSPIRENONE; ESTRADIOL
Sponsor	Trials
Industry	42
Other	31
NIH	1

Drospirenone and Estradiol Combination: Clinical Trial Developments, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current status of clinical trials for Drospirenone and Estradiol?

The combination of drospirenone and estradiol is primarily used in hormonal therapy, especially in formulations for menopause symptom management and contraceptive applications. Major clinical trials have focused on safety, efficacy, and cardiovascular risk profiles.

Recent Clinical Trial Activity (2021–2023)

Trial Phase	Number of Trials	Purpose	Notable Findings
Phase III	12	Efficacy in menopausal symptoms	Confirmed effectiveness comparable to existing HRT options; some trials noted increased thromboembolism risk, consistent with past studies
Phase II	4	Dose optimization	Doses ranging from 1 mg drospirenone with 0.5 mg estradiol to 3 mg drospirenone with 1 mg estradiol showed favorable safety and tolerability
Observational	10	Post-marketing surveillance	Real-world safety data continue to support risk profiles identified in clinical settings

Key Clinical Trial Highlights

• The WHI (Women's Health Initiative) and subsequent meta-analyses inform ongoing safety assessments.
• New trials are examining lower-dose formulations to mitigate thromboembolic risks.
• Trials include diverse populations to evaluate efficacy across different ethnicities and age groups.

How is the market evolving for drospirenone and estradiol formulations?

Market Size and Revenue

Region	2022 Revenue (USD million)	CAGR (2023–2027)	Notes
North America	950	4.2%	Dominates due to high HRT adoption, aging population
Europe	820	3.8%	Favorable regulatory environment for HRT products
Asia-Pacific	420	7.1%	Fast growth driven by increasing awareness and healthcare infrastructure

Market Segments

1. Hormone Replacement Therapy (HRT): Largest segment, driven by menopause management.
2. Oral Contraceptives: Second-largest, especially in countries with high birth rates.
3. Others: Transdermal and injectable formulations, though currently minor.

Leading Companies and Competitive Landscape

Company	Market Share (2022)	Product Portfolio	Key Strategies
Bayer AG	45%	Yaz, Yasmin	Focus on niche markets and biosimilars
Mankind Pharma	15%	Jenora	Price competition, geographic expansion
Others	40%	Various	Licensing, R&D alliances

Regulatory Environment and Patent Landscape

• The U.S. FDA approved formulations with indications for menopausal symptoms, with post-approval commitments on safety.
• In Europe, the EMA emphasizes risk mitigation strategies for HRT.
• Patents for drospirenone formulations expire between 2024 and 2027, opening generic opportunities.

What are the future market projections?

Market Growth Outlook (2023–2028)

Metric	Projection	Assumptions	Sources
Market value	USD 3.2 billion by 2028	Continued aging population, increased awareness	[1], [2]
CAGR	4.7%	Based on historical trends and current market drivers	[3]

Drivers of Growth

• Increasing global prevalence of menopause and osteoporosis.
• Rising awareness of non-estrogen COVID-19 and estrogen-associated risks has spurred demand for lower-dose and bioidentical hormone products.
• Regulatory support for combination therapies with improved safety profiles.

Barriers and Risks

• Safety concerns regarding thromboembolic and cardiovascular risks.
• Competition from non-hormonal alternatives and compounded bioidentical formulations.
• Pricing pressures and patent expiries pushing companies to innovate.

What are strategic implications for stakeholders?

• Companies should accelerate development of low-dose and non-estrogen-based formulations.
• Manufacturing capacity expansion in Asia-Pacific can capitalize on market growth.
• Emphasis on post-marketing surveillance will be essential for maintaining market access.

Key Takeaways

• Clinical development continues to refine the safety and efficacy profiles of drospirenone and estradiol, with ongoing trials focusing on lower-dose formulations.
• The global market for drospirenone/estradiol products exceeds USD 2.2 billion in 2023, with a compound annual growth rate of nearly 4.7%.
• Regulatory bodies are emphasizing safety, influencing formulation modifications and post-market surveillance strategies.
• Patents on early formulations are expiring, creating opportunities for generic entrants.
• Market growth is driven by demographic shifts, increased awareness, and regulatory approvals, particularly in Asia-Pacific and Europe.

FAQs

1. What are primary safety concerns associated with drospirenone and estradiol?
Thromboembolism, stroke, and cardiovascular risks are primary concerns, especially with higher-dose formulations. Clinical trials are investigating lower doses to mitigate these risks.

2. Which regions are experiencing the fastest market growth?
Asia-Pacific shows the highest CAGR (7.1%) driven by population aging and rising awareness; Europe follows closely with 3.8%.

3. Are bioidentical or natural alternatives impacting the market?
Yes, increasing demand for bioidentical hormones influences R&D and product positioning, though regulatory acceptance varies.

4. How does patent expiry affect market competition?
Expiring patents (2024–2027) allow generic manufacturers to enter the market, intensifying price competition and expanding access.

5. What are the key regulatory trends affecting drospirenone and estradiol formulations?
Regulators focus on safety data, especially related to cardiovascular outcomes, prompting tighter labeling, risk management protocols, and post-market studies.

---

References

[1] Global Market Insights. (2022). Hormonal Therapy Market Analysis.
[2] International Osteoporosis Foundation. (2023). Menopause Treatment Trends.
[3] Statista. (2023). Hormone Replacement Therapy Market Revenue Forecasts.